Denali Therapeutics Inc. Depreciation
Denali Therapeutics Inc. (DNLI) reported Depreciation of $5.04 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2018-11-08
- Denali Therapeutics Inc. depreciation for the quarter ending 2018-09-30 was $2.33M, a 199.10% increase year-over-year.
- Denali Therapeutics Inc. depreciation for the quarter ending 2018-06-30 was $1.85M, a 142.17% increase year-over-year.
- Denali Therapeutics Inc. depreciation for the quarter ending 2018-03-31 was $854.00K, a 16.83% increase year-over-year.
- Denali Therapeutics Inc. depreciation for the quarter ending 2017-09-30 was $778.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month |
|---|---|---|---|
| 2018-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $4.18M derived: sum of 2 quarters · filed 2018-11-08 | $5.04M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.71M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $854.00K 10-Q · filed 2018-05-11 | ||
| 2017-09-30 | $778.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.54M derived: sum of 2 quarters · filed 2018-11-08 | $2.27M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $766.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.50M 10-Q · filed 2018-08-09 | |
| 2017-03-31 | $731.00K 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |